Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Preparing “Action Guidelines” to Ensure Greater Transparency
April 24, 2015
- Expert Warns against Research-Driven Makers’ Foray into Indian Market
April 22, 2015
- JPMA to Step Up Calls for Biowaivers Using IVIVC
April 21, 2015
- MHLW to Inquire with Drug Makers about Payments to PAFSC Members
April 17, 2015
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
- APAC Approves “Good Submission Practice” Guidelines Aimed at Reducing Time to Approval in Asia
April 13, 2015
- JPA Vice President Disagrees with Exclusion of OTC-Like Drugs from Insurance Coverage
April 13, 2015
- JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
- October-December Generic Share Down 1.3 Points from Prior Qtr: JGA
March 27, 2015
- 15 Drug Makers to Jointly Purchase 150,000 Compounds for Compound Libraries Over 5-Year Period Starting in FY2015
March 27, 2015
- 1st Generation Poultices “Just One Example” for Proposal to Scrap Health Coverage for OTC-Like Drugs: Shirakawa
March 26, 2015
- Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
- JPMA to Begin Operating New Statistical Drug Database in FY2015
March 23, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
- JPWA Calls on MHLW to Narrow Down Range of Pharmacies Subjected to Medical Fee Cut Rule for Low Price Settlement Rates
March 20, 2015
- Kyokai Kenpo Aims to Increase Generic Usage Rate to 65.1%
March 20, 2015
- JHSF Calls for Tax Incentives to Promote Investment in Regenerative Medicine
March 19, 2015
- Majority of Doctors Dissatisfied with Existing Treatments for AD, Pancreatic Cancer: JHSF
March 18, 2015
- Bone-Forming Agents Most Needed for Osteoporosis in 2025: JHSF Survey
March 18, 2015
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…